L. J. Sterling

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Genes, chromosomes & cancer.

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

C. Bloomfield, J. Byrd, K. Metzeler, 2018, Blood advances.

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.

C. Bloomfield, J. Byrd, R. Larson, 2004, Annals of hematology.

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2008, International journal of oncology.

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461

C. Bloomfield, K. Mrózek, A. Carroll, 2013, Genes, chromosomes & cancer.